Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

May 19, 2025 08:00 ET | Source: Windtree Therapeutics

Windtree Therapeutics Announces Istaroxime Presentation at European Society of Cardiology Heart Failure Conference

WARRINGTON, Pa., May 19, 2025 (GLOBE NEWSWIRE) -- Windtree Therapeutics, Inc. (“Windtree” or the “Company”) (NasdaqCM: WINT), a biotechnology company focused on becoming a revenue generating company...
May 16, 2025 08:00 ET | Source: Windtree Therapeutics

Windtree Therapeutics Reports First Quarter 2025 Financial Results and Provides Key Business Updates

WARRINGTON, Pa., May 16, 2025 (GLOBE NEWSWIRE) -- Windtree Therapeutics, Inc. (“Windtree” or “the Company”) (NasdaqCM: WINT), a biotechnology company focused on becoming a revenue generating company...
May 12, 2025 08:00 ET | Source: Windtree Therapeutics

Windtree Therapeutics Announces Presentation of Preclinical Data on Istaroxime and a Selective SERCA2a Activator at the European Society of Cardiology Heart Failure Conference May 17, 2025

WARRINGTON, Pa., May 12, 2025 (GLOBE NEWSWIRE) -- Windtree Therapeutics, Inc. (“Windtree” or the “Company”) (NasdaqCM: WINT), a biotechnology company focused on becoming a revenue generating company...
May 06, 2025 08:18 ET | Source: Windtree Therapeutics

Windtree Announces Istaroxime Exclusivity and Intellectual Property Potential Strategy for US

WARRINGTON, Pa., May 06, 2025 (GLOBE NEWSWIRE) -- Windtree Therapeutics, Inc. (“Windtree” or the “Company”) (NasdaqCM: WINT), a biotechnology company focused on becoming a revenue generating company...
May 01, 2025 08:30 ET | Source: Windtree Therapeutics

Windtree Announces Strategic Transaction to Drive Revenue Generation in Support of Ongoing Therapeutic Pipeline Development

WARRINGTON, Pa., May 01, 2025 (GLOBE NEWSWIRE) -- Windtree Therapeutics, Inc. (“Windtree” or the “Company”) (NasdaqCM: WINT), a biotechnology company focused on becoming a revenue generating company...
April 15, 2025 08:00 ET | Source: Windtree Therapeutics

Windtree Therapeutics Reports Year-End 2024 Financial Results and Provides Key Business Updates

WARRINGTON, Pa., April 15, 2025 (GLOBE NEWSWIRE) -- Windtree Therapeutics, Inc. (“Windtree” or “the Company”) (NasdaqCM: WINT), a biotechnology company focused on advancing early and late-stage...
March 24, 2025 08:00 ET | Source: Windtree Therapeutics

Windtree Therapeutics Regains Compliance with Nasdaq Listing Rules

WARRINGTON, Pa., March 24, 2025 (GLOBE NEWSWIRE) -- Windtree Therapeutics, Inc. (“Windtree” or the “Company”) (NasdaqCM: WINT), a biotechnology company focused on becoming a revenue generating...
March 20, 2025 08:00 ET | Source: Windtree Therapeutics

Windtree Announces License and Supply Agreement to Become Sourcing Partner for a Small Biotech with an FDA Approved Product

WARRINGTON, Pa., March 20, 2025 (GLOBE NEWSWIRE) -- Windtree Therapeutics, Inc. (“Windtree” or the “Company”) (NasdaqCM: WINT), a biotechnology company focused on becoming a revenue generating...
March 04, 2025 08:00 ET | Source: Windtree Therapeutics

Windtree Announces Istaroxime Notice of Allowance from the U.S. Patent and Trademark Office for Acute Heart Failure

WARRINGTON, Pa., March 04, 2025 (GLOBE NEWSWIRE) -- Windtree Therapeutics, Inc. (“Windtree” or the “Company”) (NasdaqCM: WINT), a biotechnology company focused on advancing early and late-stage...
February 27, 2025 08:00 ET | Source: Windtree Therapeutics

Windtree Files Istaroxime Cardiogenic Shock and Prevention of Arrythmias Patent for India

WARRINGTON, Pa., Feb. 27, 2025 (GLOBE NEWSWIRE) -- Windtree Therapeutics, Inc. (“Windtree” or the “Company”) (NasdaqCM: WINT), a biotechnology company focused on advancing early and late-stage...